Month: June 2024

Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effects MP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 14, 2024 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced preclinical proof-of-concept data from MP0621, a multispecific cKit x CD16a x CD47 Switch-DARPin program. The data validates the Switch-DARPin...

PRESS RELEASE – PRIVILEGED INFORMATION Mont-Saint-Guibert, Belgium, June 14, 2024 7.00am CEST – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, announces that it has received the homologation judgment for the restructuring plan filed with the Enterprise Court of Nivelles. This homologation judgment makes the plan binding on all deferred creditors, and the measures provided for therein will continue until June 2029, the end of the five-year period set by law. The restructuring plan can be accessed via the following link: https://biosenic.com/sites/default/files/2024-04/PRJ_BioSenic_FR.pdf The homologation judgment closes the judicial reorganization procedure. BioSenic’s board of directors will take the necessary decisions...

WISeKey Announces Retirement of Peter Ward as Chief Financial Officer; Appoints John O’Hara as its New Chief Financial Officer Geneva, Switzerland – June 14, 2024 – Ad-Hoc announcement pursuant to Art. 53 SIX Listing Rules – WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT), today announced the retirement of Peter Ward as its Chief Financial Officer, effective June 30, 2024. The Company appoints John O’Hara as its new Chief Financial Officer, effective July 1, 2024. Following his retirement, Mr. Ward will remain a member of the Board of Directors of WISeKey. Mr. Ward joined the Company in 2008 and has served as its Chief Financial Officer since 2015. Mr. O’Hara, who currently serves as the CFO of SEALSQ Corp. (“SEALSQ”, NASDAQ:...

Fornebu, Norway – June 14, 2024 – Norwegian businesses and public sector organisations are facing more frequent and severe cyberattacks. According to a survey conducted by Norstat, 1 in 5 business leaders reported having experienced cyberattacks in the past year – a staggering 130,000 Norwegian companies. In response to this growing threat, Telenor is establishing a new cyber security company to meet these increasing demands from businesses. “We have never experienced cyber threats as frequent and severe as we do today. The business digital landscape  is under constant attack, making robust cybersecurity more critical than ever. Telenor has decided to build on its experience and expertise as one of the Norway’s strongest security players and is establishing a new cybersecurity company with Nordic ambitions,” says Sigve Brekke, CEO...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of its previously announced underwritten public offering of an aggregate of 11,250,000 shares of its common stock at an offering price of $4.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,750,000 shares of common stock at an offering price of $3.999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and other...

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a public offering price of $1.35 per share and (ii) pre-funded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors. The pre-funded warrants will be immediately exercisable, and may be exercised at any time after their original issuance. The purchase price of each pre-funded warrant sold in the offering will be equal to the price at which a share of common stock is sold in the offering, minus $0.0001, and the exercise price of each pre-funded warrant will equal $0.0001 per share. In connection with the offering, Gain has granted the underwriter a 30-day...

NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced the pricing of its underwritten public offering of 7,435,898 shares of its common stock at a price to the public of $39.00 per share. In addition, in lieu of issuing common stock to certain investors, the company is offering pre-funded warrants to purchase 1,538,501 shares of its common stock at a purchase price of $38.999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The aggregate gross proceeds to the company from this offering is expected to be $350 million,...

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that Arm Holdings plc (Nasdaq: ARM), will become a component of the Nasdaq-100 Index® (Nasdaq: NDX®), the Nasdaq-100 Equal Weighted™ Index (Nasdaq: NDXE™), the Nasdaq-100 Tech Sector™ Index (Nasdaq: NDXT™), the Nasdaq-100 Technology Sector Market-Cap Weighted™ Index (Nasdaq: NDXTMC™), and the Nasdaq-100 Technology Sector Adjusted Market-Cap Weighted™ Index (Nasdaq: NDXT10™) prior to market open on Monday, June 24, 2024. Arm Holdings plc will replace Sirius XM Holdings Inc. (Nasdaq: SIRI) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. Sirius XM will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (Nasdaq: NDXX™), the Nasdaq-100 ESG Index (Nasdaq:...

KIRKLAND, Wash., June 13, 2024 (GLOBE NEWSWIRE) — Monolithic Power Systems, Inc. (Nasdaq: MPWR), a global company that provides high-performance, semiconductor-based power electronics solutions, announced today its second quarter dividend of $1.25 per common share to all stockholders of record as of the close of business on June 28, 2024. The dividend will be paid on July 15, 2024. Safe Harbor Statement This news release includes “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current expectations, estimates and projections about our business and industry, management’s beliefs, and certain assumptions made by us, all of which are subject to change. Forward-looking statements...

Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024 MELBOURNE, Australia and PRINCETON, N.J., June 13, 2024 (GLOBE NEWSWIRE) — Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the successful completion of the institutional component of the capital raising announced on Wednesday, 12 June 2024. The non-underwritten institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of the partially underwritten 1 for 1.22 pro-rata accelerated non-renounceable entitlement...